Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT07246005
PHASE2

LVT DURATION: Pilot Study of Anticoagulation Duration for Left Ventricular Thrombus

Sponsor: Queen Mary University of London

View on ClinicalTrials.gov

Summary

The LVT DURATION (Optimal Duration of Anticoagulation for LV Thrombus) is a pilot study planned to assess the practicalities of conducting a randomised control trial (RCT) whilst establishing data around the ideal duration of anticoagulation in the treatment of LV thrombus. The main objectives of the study are: * To assess the practicalities of conducting an RCT with regard to recruitment, retention, and outcome measurement. * To identify the optimal length of anticoagulation in the treatment of LV Thrombus After randomisation participants will: * Continue their prescribed oral anticoagulant for the remainder of the trial * Discontinue their prescribed oral anticoagulant for the remainder of the trial

Official title: A Randomised Pilot Study Assessing the Optimal Duration of Anticoagulation for Left Ventricular Thrombus

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

120

Start Date

2026-12-01

Completion Date

2027-12-01

Last Updated

2026-02-27

Healthy Volunteers

No

Interventions

DRUG

Continue rivaroxaban or apixaban or warfarin

The study is asessing the impact of discontinuation of oral anticoagulation in patients with LV thrombus diagnosis.

DRUG

Discontinue rivaroxaban or apixaban or warfarin

discontinue rivaroxaban or apixaban or warfarin

Locations (1)

St Bartholomews Hospital

London, United Kingdom